Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
Background: Oropharyngeal dysphagia (OD) is a common complication in/post ICU patients that have been with intubation/mechanical ventilation or with tracheotomies or NG tubes, in patients with acute respiratory infection/pneumonia/respiratory insufficiency with a severe disease needing high concentration of oxygen or noninvasive mechanical ventilation and also in patients discharged from acute hospitals to rehabilitation centers, nursing homes or other facilities. All these situations are common for COVID-19 patients that are currently filling our hospitals due to the pandemic expansion of SARS-CoV-2. OD is associated to prolonged hospitalization, dehydration and severe nutritional and respiratory complications -aspiration pneumonia-, hospital readmissions and mortality. Aim: to assess the prevalence of OD and nutritional risk in these patients and to know their needs of compensatory treatment following the application of an early intervention, and to assess whether OD and malnutrition are indicators of poor prognosis for COVID-19 patients. Methods: prospective study in which we will use the volume-viscosity swallowing test (V-VST) to assess the prevalence of OD, and NRS2002 to assess the nutritional risk in admitted patients with confirmed COVID-19 at the Consorci Sanitari del Maresme, Catalonia, Spain. We will register also results of the EAT-10, nutritional status, the needs of compensatory treatments of these patients following an early intervention with fluid and nutritional adaptation and use of nutritional supplements. We will also collect other clinical variables from medical history of the patient related to hospitalization and we will follow the clinical complications and nutritional status at 3 and 6 months follow up.
Description: Changes in the prevalence of oropharyngeal dysphagia according to a clinical assessment tool, the Volume-Viscosity Swallowing Test (V-VST).
Measure: Changes in the prevalence of oropharyngeal dysphagia Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the eating assessment tool (EAT-10 score). A tool that goes from 0 to 40 points and indicates that the patient is at risk of oropharyngeal dysphagia if he/she presents 3 or more points
Measure: Changes in the swallowing screening Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the percentage of patients with impairements in efficacy and/or safety of swallow.
Measure: Changes in the swallowing status Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the nutritional status of study patients (% malnourished, at risk of malnutrition or wellnourished).
Measure: Changes in the nutritonal status of study patient's. Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the fluid (volume and viscosity) requirements of study patients.
Measure: Changes in the needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation). Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the nutritional adaptation requirements (type of diet and need of nutritional supplementation).
Measure: Changes in the needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation). Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the incidence of hospital readmissions: number of hospital readmissions/patient/6 months.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (incidence of readmissions). Time: 3 and 6 months from inclusion.Description: Changes in the prevalence: % of patients with hospital readmissions during the follow-up.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (prevalence of readmissions). Time: 3 and 6 months from inclusion.Description: Incidence: number of visits to the emergency department/patient/ 3 or 6 months.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (number of visits to emergency department). Time: 3 and 6 months from inclusion.Description: Prevalence: % of patients visiting the emergency department during the follow-up.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (percentage of visits to emergency department). Time: 3 and 6 months from inclusion.Description: Incidence of respiratory infections (including pneumonia, and COPD exacerbations).
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (respiratory complications). Time: 3 and 6 months from inclusion.Description: 3 and 6 months mortality.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (mortality). Time: 3 and 6 months from inclusion.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports